Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2861	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2859	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2860	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2862
HGNC, UniProt	https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7881, http://www.uniprot.org/uniprot/P46531	https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7882, http://www.uniprot.org/uniprot/Q04721	https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7883, http://www.uniprot.org/uniprot/Q9UM47	https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7884, http://www.uniprot.org/uniprot/Q99466
Comments	Various types of activating and inactivating NOTCH1 mutations have been reported to be associated with human diseases, for example: aortic valve disease [http://www.ncbi.nlm.nih.gov/pubmed/16025100?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18593716?dopt=AbstractPlus], Adams‐Oliver syndrome 5 [http://www.ncbi.nlm.nih.gov/pubmed/25132448?dopt=AbstractPlus], T‐cell acute lymphoblastic leukemia (T‐ALL) [http://www.ncbi.nlm.nih.gov/pubmed/15472075?dopt=AbstractPlus], chronic lymphocytic leukemia (CLL) [http://www.ncbi.nlm.nih.gov/pubmed/21642962?dopt=AbstractPlus] and head and neck squamous cell carcinoma [http://www.ncbi.nlm.nih.gov/pubmed/21798897?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21798893?dopt=AbstractPlus].	–	–	Notch receptor 4 is a potential therapeutic molecular target for triple‐negative breast cancer [http://www.ncbi.nlm.nih.gov/pubmed/25993190?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24403446?dopt=AbstractPlus].